Heesch C M, Eichhorn E J
Cardiac Catheterization Laboratory, University of Texas Southwestern.
Ann Emerg Med. 1994 Dec;24(6):1154-60. doi: 10.1016/s0196-0644(94)70248-9.
Clinical studies on the use of magnesium in acute myocardial infarction have yielded contradictory results. While the exact reasons for these discrepancies are unclear, it appears that the timing of magnesium administration is crucial to the success or failure of therapy. Although some studies have shown a significant reduction in the odds of death with this agent, the exact reasons underlying this possible benefit are not yet fully understood. A reduction in arrhythmias, inhibition of thrombus generation, changes in coronary and peripheral hemodynamics, and the limitation of ischemic damage and reperfusion injury have been inferred as possible mechanisms. IV magnesium is inexpensive and easy to administer, and has minimal side effects. While further research on magnesium therapy in ischemic states is warranted, the early use of IV magnesium should be considered in selected patients with suspected acute myocardial infarction.
关于镁在急性心肌梗死中应用的临床研究结果相互矛盾。虽然这些差异的确切原因尚不清楚,但似乎镁给药的时机对治疗的成败至关重要。尽管一些研究表明使用该药物可显著降低死亡几率,但这种潜在益处背后的确切原因尚未完全明确。心律失常减少、血栓形成抑制、冠状动脉和外周血流动力学改变以及缺血损伤和再灌注损伤的限制被推断为可能的机制。静脉注射镁剂价格低廉且易于给药,副作用极小。虽然有必要对缺血状态下的镁治疗进行进一步研究,但对于选定的疑似急性心肌梗死患者,应考虑早期使用静脉注射镁剂。